Clinical Trials
47 trialsIndividual Patient Compassionate Use of Mirdametinib
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Expanded Access [11C] Methionine PET Imaging
St. Jude Children's Research Hospital
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Children's Hospital of Philadelphia
ITM11 Expanded Access Program
ITM Solucin GmbH
Expanded Access to Gallium Maltolate (GaM)
Imaging Biometrics, LLC
An Intermediate Expanded Use Trial of DFMO
Milton S. Hershey Medical Center
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Fecal Microbiota Transplant for Neuroblastoma in a Single Patient
ProgenaBiome
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
EAP
Roswell Park Cancer Institute
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Jazz Pharmaceuticals
131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults
Memorial Sloan Kettering Cancer Center
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
Second Life Therapeutics
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
University of California, San Francisco
18F-Floretyrosine Expanded Access Program
Telix Pharmaceuticals (Innovations) Pty Limited
Expanded Access Program for GBM Subjects
Rznomics, Inc.
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
University of Texas Southwestern Medical Center
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
Oblato, Inc.
Vorasidenib Expanded Access Program
Servier
Expanded Access Program for Avapritinib
Blueprint Medicines Corporation
TVI-Brain-1 in Expanded Access Patient
TVAX Biomedical
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Day One Biopharmaceuticals, Inc.
Treatment of Recurrent GBM With APG-157 Via Expanded Access
Aveta Biomics, Inc.
TRIANGLE
Petrov, Andrey
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
Northwell Health
Expanded Access for KHK2455
Kyowa Kirin Co., Ltd.
Glioblastoma and Individualized Therapies
Zentrum fur Humangenetik Tuebingen
Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Children's Hospital Medical Center, Cincinnati
Expanded Access Protocol Using 131I-MIBG
Jubilant DraxImage Inc.
18F-FDOPA PET in Neuroendocrine Tumours
British Columbia Cancer Agency
EAP for the Treatment of Glioblastoma With PVSRIPO
Istari Oncology, Inc.
Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas
Jazz Pharmaceuticals
Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma
South Plains Oncology Consortium
Individual Patient Compassionate Use of GX-I7
Genexine, Inc.
Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
Jazz Pharmaceuticals
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
University of California, San Francisco
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
AstraZeneca
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Seagen Inc.
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Massachusetts Eye and Ear Infirmary
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
Center Trials & Treatment
Expanded Access to ABT-414
AbbVie
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Expanded Access for Pembrolizumab (MK-3475)
Center Trials & Treatment
CDX-110
Celldex Therapeutics
Expanded Access to ANG1005 for Individual Patients
Angiochem Inc
DCVax-L EAP
Northwest Biotherapeutics
Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma
GE Healthcare